John R. Hughes, MD - Addiction Psychiatry

 

Dr. John R. Hughes reviews medical content for Healthwise, a nonprofit organization with a mission to help people make better health decisions. His major clinical research focuses include nicotine dependence, human behavioral pharmacology of drug abuse, and alcohol and drug abuse. Dr. Hughes received the Ove Ferno Award for research in nicotine dependence and the Alton Ochsner Award Relating Smoking and Health. He is a cofounder and past president of the Society for Research on Nicotine and Tobacco and the Association for the Treatment of Tobacco Use and Dependence. He has written over 350 publications on nicotine and other drug dependencies and is one of the 25 most-cited tobacco scientists. Dr. Hughes has been a consultant on tobacco policy to the World Health Organization, the U.S. Food and Drug Administration, and the White House.

Education and Training

MD: University of Mississippi Medical School, Jackson, MS, 1975

Internship in Internal Medicine: University of Mississippi Medical School, Jackson, MS, 1975–1976

Residency in Psychiatry: University of Mississippi Medical School, Jackson, MS, 1976–1978

Residency in Psychiatry: University of Pittsburgh, Western Psychiatric Institute and Clinic, Pittsburgh, PA, 1978–1979

NIH Postdoctoral Fellow: University of Minnesota School of Public Health, Minneapolis, MN, 1979–1981

Certifications

Psychiatry, American Board of Psychiatry and Neurology

Addiction Psychiatry, American Board of Psychiatry and Neurology

Academic Appointments

University of Vermont, Departments of Psychiatry, Psychology, and Family Practice, Burlington, VT:

  • Professor, 1991–present
  • Associate Professor, 1985–1991

Visiting Professor, Pharmacia and Upjohn, Helsingborg, Sweden, 1996

Assistant Professor, University of Minnesota, Department of Psychiatry, Division of Epidemiology, Minneapolis, MN, 1981–1985

Financial Disclosure

The final approval of Healthwise content is always made by a clinician with no financial conflicts.

Dr. Hughes has received fees from almost all of the companies that develop smoking cessation services, medications, and devices and from various public and private organizations that promote tobacco control.

Current as of: January 10, 2014